Provided by Tiger Trade Technology Pte. Ltd.

OPUS GENETICS INC

6.04
-0.0300-0.49%
Post-market: 5.95-0.0861-1.43%19:58 EDT
Volume:4.66M
Turnover:28.44M
Market Cap:502.50M
PE:-4.67
High:6.58
Open:6.16
Low:5.77
Close:6.07
52wk High:7.07
52wk Low:1.35
Shares:83.20M
Float Shares:65.21M
Volume Ratio:0.33
T/O Rate:7.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2925
EPS(LYR):-0.8000
ROE:-4796.52%
ROA:-48.06%
PB:-38.70
PE(LYR):-7.55

Loading ...

Opus Genetics Inc : TD Cowen Initiates Coverage with Buy Rating

THOMSON REUTERS
·
Jul 29

Opus Genetics initiated with a Buy at TD Cowen

TIPRANKS
·
Jul 29

Analysts Offer Insights on Healthcare Companies: Forte Biosciences (FBRX), Sarepta Therapeutics (SRPT) and Opus Genetics (IRD)

TIPRANKS
·
Jul 10

Opus Genetics sets September timeline for retinal disease trial data

TIPRANKS
·
Jul 09

Opus Genetics - to Announce Opgx-best1 Three-month Topline Data from Cohort 1 in September 2026

THOMSON REUTERS
·
Jul 09

Analysts Are Bullish on Top Healthcare Stocks: Tenet Healthcare (THC), Opus Genetics (IRD)

TIPRANKS
·
Jul 08

Analysts Are Bullish on These Healthcare Stocks: CVRx (CVRX), Opus Genetics (IRD)

TIPRANKS
·
Jul 07

Opus Genetics: FDA-Backed Phase 3 Path and Strong Early Efficacy Support Reiterated Buy on IRD with Unchanged $10 Price Target

TIPRANKS
·
Jul 07

Opus Genetics Price Target Maintained with a $12.00/share by BTIG

Dow Jones
·
Jul 07

Opus Genetics FDA alignment further de-risks path to market, says Chardan

TIPRANKS
·
Jul 06

Opus Genetics Posts Press Release on FDA Alignment for Opgx-lca5 Phase 3 Trial Design

Reuters
·
Jul 06

Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for Opgx-lca5 in Lca5-associated Inherited Retinal Disease

THOMSON REUTERS
·
Jul 06

Opus Genetics - FDA Allows Bla Submission Based on 6-month Efficacy Data for Opgx-lca5

THOMSON REUTERS
·
Jul 06

Opus Genetics - to Initiate Phase 3 Dosing in Q4 2026

THOMSON REUTERS
·
Jul 06

Opus Genetics Shares Rise on Addition to Russell Indexes

Dow Jones
·
Jun 26

Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes

THOMSON REUTERS
·
Jun 26

JonesTrading Sticks to Their Buy Rating for Opus Genetics (IRD)

TIPRANKS
·
Jun 25

Opus Genetics Inc : RBC Initiates Coverage With Outperform Rating; Price Target $10

THOMSON REUTERS
·
Jun 23

Opus Genetics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Jun 19

Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Opus Genetics (IRD)

TIPRANKS
·
Jun 18